Literature DB >> 12463442

Socioeconomic consequences of ankylosing spondylitis.

A Boonen1.   

Abstract

Since ankylosing spondylitis usually starts at an early age, the socioeconomic impact of the disease on the patient and on society can be important. Several studies have reported substantial work disability, but there is considerable variation among countries. While withdrawal from work is associated with an older age at diagnosis and manual jobs or a lower educational level, sick leave in those with a paying job is associated with disease activity and physical functioning. The yearly mean total (direct and productivity) costs of AS are US$6,720 per patient in the USA and Euro 9,462 per patient in Europe when the human capital approach is used to calculate the productivity costs. A cost-effectiveness study on spa-therapy in AS shows that the clinical benefits of (expensive) treatments can be reached within acceptable costs.

Entities:  

Mesh:

Year:  2002        PMID: 12463442

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  20 in total

1.  The effect of total hip replacement on employment in patients with ankylosing spondylitis.

Authors:  Chongru He; Xiaokang He; Wenwen Tong; Wei Zheng; Tianfang Zhang; Jinzhu Zhao; Weidong Xu
Journal:  Clin Rheumatol       Date:  2016-10-12       Impact factor: 2.980

Review 2.  Late-onset ankylosing spondylitis and related spondylarthropathies: clinical and radiological characteristics and pharmacological treatment options.

Authors:  Eric Toussirot; Daniel Wendling
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

3.  Cross-cultural adaptation and validation of the Chinese version of the Health Assessment Questionnaire for the Spondyloarthropathies (HAQ-S).

Authors:  DeLin Liu; Chen Zhang; Chen Wang; Jiao Liu; DaHe Li; Jia Li; Weidong Xu
Journal:  Clin Rheumatol       Date:  2017-07-27       Impact factor: 2.980

4.  Cardiovascular risk estimation in young patients with ankylosing spondylitis: A new model based on a prospective study in Constanta County, Romania.

Authors:  Mihaela Ionescu; Paris Ionescu; Adrian Paul Suceveanu; Anca Pantea Stoian; Ion Motofei; Valeriu Ardeleanu; Irinel-Raluca Parepa
Journal:  Exp Ther Med       Date:  2021-03-22       Impact factor: 2.447

5.  Socioeconomic impact of ankylosing spondylitis in Morocco.

Authors:  Hanan Rkain; Fadoua Allali; Aziza Bentalha; Noufissa Lazrak; Redouane Abouqal; Najia Hajjaj-Hassouni
Journal:  Clin Rheumatol       Date:  2007-04-25       Impact factor: 2.980

6.  Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.

Authors:  A Calin; B A C Dijkmans; P Emery; M Hakala; J Kalden; M Leirisalo-Repo; E M Mola; C Salvarani; R Sanmartí; J Sany; J Sibilia; J Sieper; S van der Linden; E Veys; A M Appel; S Fatenejad
Journal:  Ann Rheum Dis       Date:  2004-09-02       Impact factor: 19.103

Review 7.  [Biologics in the early treatment of ankylosing spondylitis and related forms of spondyloarthritis].

Authors:  Hans-Eckhard Langer
Journal:  Wien Med Wochenschr       Date:  2008

8.  Responsiveness of the EuroQoL 5-Dimension (EQ-5D) questionnaire in patients with spondyloarthritis.

Authors:  Helen Hoi Lun Tsang; Jason Pui Yin Cheung; Carlos King Ho Wong; Prudence Wing Hang Cheung; Chak Sing Lau; Ho Yin Chung
Journal:  BMC Musculoskelet Disord       Date:  2021-05-14       Impact factor: 2.362

9.  Are clinical measures influenced by various ethnic origins in Iranian patients with ankylosing spondylitis?A pilot study.

Authors:  Sasan Fallahi; Ahmad Reza Jamshidi; Mahdi Mahmoudi; Mostafa Qorbani
Journal:  Caspian J Intern Med       Date:  2014

10.  Biologic Treatment Registry Across Canada (BioTRAC): a multicentre, prospective, observational study of patients treated with infliximab for ankylosing spondylitis.

Authors:  Proton Rahman; Denis Choquette; William G Bensen; Majed Khraishi; Andrew Chow; Michel Zummer; Saeed Shaikh; Maqbool Sheriff; Sanjay Dixit; Dalton Sholter; Eliofotisti Psaradellis; John S Sampalis; Vincent Letourneau; Allen J Lehman; François Nantel; Emmanouil Rampakakis; Susan Otawa; May Shawi
Journal:  BMJ Open       Date:  2016-04-05       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.